Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Irinotecan with Radiation in Locally Advanced NSCLC
NCT02275806Phase 2Terminated
- Sponsor
- Leo W. Jenkins Cancer Center
- Start
- Oct 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in non-small cell lung cancer (NSCLC), sponsored by Leo W. Jenkins Cancer Center. Primary endpoints: Median Survival Rate at 3 years, Three Year Survival Rate at 3 years and 1 more. Started Oct 2014; status: terminated.
02
Drugs
irinotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02275806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275806.